glp-1 obesity drugs Four Strategies for Competing in the Crowded Drug Marketplace Pediatric trials aim to expand

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

In another study, more than one-third hospitalised COVID-19 survivors continued to have persistent radiological lung abnormalities at 3-year follow-up, which were associated with respiratory symptoms and reduced diffusion capacity [9]

Elevating the levels of cytokines such as TNF- , IL-1, and IL-6 due to gut-derived toxins may contribute to chronic inflammation (65, 66)

Extending its weight loss portfolio The successful phase 3 trial for Lilly's orforglipron brings the drug one step closer to being approved by the U.S

Research suggests that it may hold promise in addressing a myriad of health concerns, from gastrointestinal issues to neuropathic pain